Komodo’s flagship product, the AtomicDEX, has been in development since 2013. The decentralized exchange remains a topic of discussion as it continues to develop its interoperability while keeping safety as a core focus.
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for treatment-resistant depression (TRD).